Merck agrees to let other drug makers make its Covid pill

&Tab;&Tab;<div class&equals;"wpcnt">&NewLine;&Tab;&Tab;&Tab;<div class&equals;"wpa">&NewLine;&Tab;&Tab;&Tab;&Tab;<span class&equals;"wpa-about">Advertisements<&sol;span>&NewLine;&Tab;&Tab;&Tab;&Tab;<div class&equals;"u top&lowbar;amp">&NewLine;&Tab;&Tab;&Tab;&Tab;&Tab;&Tab;&Tab;<amp-ad width&equals;"300" height&equals;"265"&NewLine;&Tab;&Tab; type&equals;"pubmine"&NewLine;&Tab;&Tab; data-siteid&equals;"111265417"&NewLine;&Tab;&Tab; data-section&equals;"1">&NewLine;&Tab;&Tab;<&sol;amp-ad>&NewLine;&Tab;&Tab;&Tab;&Tab;<&sol;div>&NewLine;&Tab;&Tab;&Tab;<&sol;div>&NewLine;&Tab;&Tab;<&sol;div><p>Pharmaceutical company Merck agreed to allow other drug makers worldwide to produce its Covid-19 pill&comma; in a move aimed at helping millions of people in poorer countries get access to the potentially life-saving drug&comma; a United Nations-backed public health organisation said&period;<&sol;p>&NewLine;<p>The Medicines Patent Pool said in a statement that it had signed a voluntary licensing agreement for molnupiravir with Merck and its partner Ridgeback Biotherapeutics&period;<&sol;p>&NewLine;<p>The agreement will allow the Medicines Patent Pool to grant further licences to qualified companies who are approved to make the drug&period;<&sol;p>&NewLine;<p>Neither drug maker will receive royalties under the agreement for as long as the World Health Organisation &lpar;WHO&rpar; deems Covid-19 to be global emergency&period; Molnupiravir is the first pill that has been shown to treat the disease&period;<&sol;p>&NewLine;<p>Charles Gore&comma; the executive director of the Medicines Patent Pool&comma; said the early results for molnupiravir were &OpenCurlyDoubleQuote;compelling” and that he hoped this first voluntary licensing agreement for a Covid-19 treatment would lead to others&period;<&sol;p>&NewLine;<p>Despite repeated requests from governments and health officials&comma; no vaccine makers have agreed to a similar deal&period; A hub set up by WHO in South Africa intended to share messenger RNA vaccine recipes and technologies has not enticed a single pharmaceutical to join&period;<&sol;p>&NewLine;<p>Merck has requested its pill be licensed by both the US Food and Drug Administration and the European Medicines Agency&comma; decisions that could come within weeks&period;<&sol;p>&NewLine;<p>Merck reported this month that molnupiravir cut hospital admissions and deaths by half among patients with early symptoms of Covid-19&period; The results were so strong that independent medical experts monitoring the trial recommended stopping it early&period;<&sol;p>&NewLine;<p>An antiviral pill that people could take at home to reduce their symptoms and speed recovery could prove groundbreaking&comma; easing the crushing caseload on hospitals and helping to curb outbreaks in poorer countries with weak health care systems&period;<&sol;p>&NewLine;<p>It would also bolster a two-pronged approach to the pandemic&colon; treatment by way of medication and prevention&comma; primarily through vaccinations&period;<&sol;p>&NewLine;<p>The charity Doctors Without Borders welcomed the agreement Merck struck to share its Covid-19 pill&comma; but said it did not go far enough&period;<&sol;p>&NewLine;<p>&OpenCurlyDoubleQuote;The licence excludes key upper-middle-income countries like Brazil and China from its territory&comma; where there are strong&comma; established capacity to produce and supply antiviral medicines&comma;” said Yuanqiong Hu&comma; a senior legal and policy adviser at Doctors Without Borders&comma; who called the deal &OpenCurlyDoubleQuote;disappointing”&period;<&sol;p>&NewLine;&Tab;&Tab;&Tab;<div style&equals;"padding-bottom&colon;15px&semi;" class&equals;"wordads-tag" data-slot-type&equals;"belowpost">&NewLine;&Tab;&Tab;&Tab;&Tab;<div id&equals;"atatags-dynamic-belowpost-68ed301f4a5d4">&NewLine;&Tab;&Tab;&Tab;&Tab;&Tab;<script type&equals;"text&sol;javascript">&NewLine;&Tab;&Tab;&Tab;&Tab;&Tab;&Tab;window&period;getAdSnippetCallback &equals; function &lpar;&rpar; &lbrace;&NewLine;&Tab;&Tab;&Tab;&Tab;&Tab;&Tab;&Tab;if &lpar; false &equals;&equals;&equals; &lpar; window&period;isWatlV1 &quest;&quest; false &rpar; &rpar; &lbrace;&NewLine;&Tab;&Tab;&Tab;&Tab;&Tab;&Tab;&Tab;&Tab;&sol;&sol; Use Aditude scripts&period;&NewLine;&Tab;&Tab;&Tab;&Tab;&Tab;&Tab;&Tab;&Tab;window&period;tudeMappings &equals; window&period;tudeMappings &vert;&vert; &lbrack;&rsqb;&semi;&NewLine;&Tab;&Tab;&Tab;&Tab;&Tab;&Tab;&Tab;&Tab;window&period;tudeMappings&period;push&lpar; &lbrace;&NewLine;&Tab;&Tab;&Tab;&Tab;&Tab;&Tab;&Tab;&Tab;&Tab;divId&colon; 'atatags-dynamic-belowpost-68ed301f4a5d4'&comma;&NewLine;&Tab;&Tab;&Tab;&Tab;&Tab;&Tab;&Tab;&Tab;&Tab;format&colon; 'belowpost'&comma;&NewLine;&Tab;&Tab;&Tab;&Tab;&Tab;&Tab;&Tab;&Tab;&rcub; &rpar;&semi;&NewLine;&Tab;&Tab;&Tab;&Tab;&Tab;&Tab;&Tab;&rcub;&NewLine;&Tab;&Tab;&Tab;&Tab;&Tab;&Tab;&rcub;&NewLine;&NewLine;&Tab;&Tab;&Tab;&Tab;&Tab;&Tab;if &lpar; document&period;readyState &equals;&equals;&equals; 'loading' &rpar; &lbrace;&NewLine;&Tab;&Tab;&Tab;&Tab;&Tab;&Tab;&Tab;document&period;addEventListener&lpar; 'DOMContentLoaded'&comma; window&period;getAdSnippetCallback &rpar;&semi;&NewLine;&Tab;&Tab;&Tab;&Tab;&Tab;&Tab;&rcub; else &lbrace;&NewLine;&Tab;&Tab;&Tab;&Tab;&Tab;&Tab;&Tab;window&period;getAdSnippetCallback&lpar;&rpar;&semi;&NewLine;&Tab;&Tab;&Tab;&Tab;&Tab;&Tab;&rcub;&NewLine;&Tab;&Tab;&Tab;&Tab;&Tab;<&sol;script>&NewLine;&Tab;&Tab;&Tab;&Tab;<&sol;div>&NewLine;&Tab;&Tab;&Tab;<&sol;div>


Discover more from London Glossy Post

Subscribe to get the latest posts sent to your email.

- Advertisement -
Exit mobile version